1. Home
  2. LGCB vs CTXR Comparison

LGCB vs CTXR Comparison

Compare LGCB & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LGCB

Linkage Global Inc

HOLD

Current Price

$0.55

Market Cap

15.7M

Sector

N/A

ML Signal

HOLD

Logo Citius Pharmaceuticals Inc.

CTXR

Citius Pharmaceuticals Inc.

HOLD

Current Price

$0.71

Market Cap

18.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LGCB
CTXR
Founded
2011
2007
Country
Japan
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.7M
18.9M
IPO Year
2023
2010

Fundamental Metrics

Financial Performance
Metric
LGCB
CTXR
Price
$0.55
$0.71
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$6.00
AVG Volume (30 Days)
127.9K
789.8K
Earning Date
01-30-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
43.38
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$147.57
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.43
$0.57
52 Week High
$3.10
$2.38

Technical Indicators

Market Signals
Indicator
LGCB
CTXR
Relative Strength Index (RSI) 17.73 44.17
Support Level N/A $0.68
Resistance Level $2.23 $0.99
Average True Range (ATR) 0.12 0.07
MACD -0.03 -0.02
Stochastic Oscillator 11.85 29.43

Price Performance

Historical Comparison
LGCB
CTXR

About LGCB Linkage Global Inc

Linkage Global Inc is a cross-border e-commerce integrated service provider. It provides international e-commerce merchants, overseas brands, import and export trading enterprises, etc. with a globally selected supply chain, digital marketing, e-commerce training, international store, ERP and e-commerce software, social e-commerce and other e-commerce integrated services. The company has two operating segments: Extend from Japan, and Other Subsidiaries from Hong Kong. The company is Committed to building a one-stop cross-border integrated service platform to make cross-border trade easier. Company operates in Japan, Hong Kong and China, with maximum revenue from Japan.

About CTXR Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.

Share on Social Networks: